Squarepoint’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-293,586
| Closed | -$64.9M | – | 4332 |
|
|
2025
Q4 | $64.9M | Buy |
+293,586
| New | +$47.5M | 0.07% | 319 |
|
|
2021
Q4 | – | Sell |
-4,371
| Closed | -$196K | – | 3191 |
|
|
2021
Q3 | $196K | Sell |
4,371
-1,553
| -26% | -$59K | ﹤0.01% | 2495 |
|
|
2021
Q2 | $239K | Sell |
5,924
-3,435
| -37% | -$145K | ﹤0.01% | 2688 |
|
|
2021
Q1 | $498K | Buy |
9,359
+4,661
| +99% | +$230K | ﹤0.01% | 2022 |
|
|
2020
Q4 | $188K | Buy |
4,698
+1,224
| +35% | +$60.9K | ﹤0.01% | 2537 |
|
|
2020
Q3 | $198K | Sell |
3,474
-988
| -22% | -$69.8K | ﹤0.01% | 2097 |
|
|
2020
Q2 | $329K | Buy |
4,462
+3,926
| +732% | +$254K | 0.01% | 1540 |
|
|
2020
Q1 | $27K | Buy |
+536
| New | +$32.1K | ﹤0.01% | 1762 |
|
|
2017
Q4 | – | Sell |
-1,030
| Closed | -$167K | – | 2107 |
|
|
2017
Q3 | $167K | Buy |
+1,030
| New | +$147K | ﹤0.01% | 1435 |
|
Squarepoint's CDTX Position: Q1 2026 in Review
Squarepoint sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 293,586 shares — an estimated $64.9M sold.
Squarepoint first reported a position in CDTX in Q3 2017 and held it in 9 quarters. The position peaked at $64.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Squarepoint reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Squarepoint sold 293,586 Cidara Therapeutics shares in Q1 2026, an estimated $64.9M.
- Squarepoint first reported a position in Cidara Therapeutics in Q3 2017 and held it in 9 quarters.
- Squarepoint's Cidara Therapeutics position peaked at $64.9M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.